PEGylation Advances Targeted mRNA Polyplex Delivery and Stability

Study Background and Research Question

Therapeutic mRNA holds promise for treating a range of diseases from genetic disorders to cancer. However, the inherent instability and poor cellular uptake of naked mRNA necessitate the development of effective delivery vehicles. While lipid nanoparticles (LNPs) have become the gold standard for clinical mRNA delivery, their formulation complexity and production challenges motivate the search for alternative non-viral carriers. Polyplexes—complexes of nucleic acids with cationic polymers or peptides—offer simplified preparation and potential for customization, but often struggle with colloidal instability and limited targeting capability. The central question addressed by Folda et al. (2025) is whether PEGylation—incorporating polyethylene glycol (PEG) lipids—can enhance the stability and targeting of lipo-xenopeptide (LAF–XP) mRNA polyplexes, and how this modification impacts their transfection efficiency and biosafety.

Key Innovation from the Reference Study

The study introduces a modular platform for mRNA complexation using double-pH-responsive lipo-xenopeptides (XP) blended with PEGylated lipids. By varying PEG-lipid ratios and LAF–XP composition, the authors systematically dissect the effects of PEGylation on colloidal stability, protein corona formation, and ligand-mediated targeting. Notably, the use of azido-functionalized PEG-lipids (DSPE-PEG-N3) facilitates the attachment of targeting ligands via strain-promoted azide-alkyne cycloaddition (SPAAC), enabling cell type-specific delivery. This approach overcomes two major bottlenecks: (1) preventing salt/protein-induced aggregation in biological fluids, and (2) restoring targeted transfection in the presence of dense PEG shields—a phenomenon termed the "PEG dilemma."

Methods and Experimental Design Insights

The authors formulated mRNA polyplexes by combining LAF–XP peptides with either DMG-PEG 2 kDa or DSPE-PEG-N3 2 kDa at defined molar ratios (1.5–20%). Physical stability was assessed by dynamic light scattering and aggregation assays in the presence of salt, serum, and fibrinogen. Transfection efficiency was evaluated in vitro using EGFR-positive cell lines, with and without ligand functionalization. For cell targeting, DSPE-PEG-N3 was post-modified with DBCO-conjugated EGFR ligands via SPAAC chemistry. In vivo, colloidal stability and biosafety were assessed following intravenous administration in animal models. The design allowed the authors to decouple the effects of PEG density, peptide composition, and ligand presence on key performance metrics.

Protocol Parameters

• Polyplex formulation: Mix mRNA with LAF–XP and PEG-lipid in aqueous buffer; optimize PEG-lipid at 1.5–3% for stability without loss of transfection efficiency.
• Protein corona minimization: Higher PEG ratios (10–20%) reduce protein adsorption but may dampen transfection unless ligand targeting is included.
• Ligand functionalization: Use DSPE-PEG-N3 and SPAAC to attach cell-specific ligands post-formulation; restore targeted delivery in PEG-shielded complexes.
• In vivo administration: Evaluate biosafety and stability by intravenous injection; monitor for aggregation and tissue-specific expression.

Core Findings and Why They Matter

PEGylation at low ratios (1.5–3% DMG-PEG) markedly improved colloidal stability, preventing salt- and serum-induced aggregation while preserving transfection efficiency—a key advance for mRNA delivery and transfection workflows. More highly PEGylated complexes (10–20%) achieved robust protein corona resistance but suffered reduced gene delivery unless equipped with a targeting ligand. The inclusion of an EGFR-targeting ligand via click chemistry successfully restored high transfection efficiency in EGFR-positive cells, demonstrating the utility of this modular approach. Notably, more neutral, LAF-rich polyplexes inherently exhibited low fibrinogen binding even in the absence of PEG, highlighting the role of carrier composition in protein corona dynamics. In vivo, stabilized polyplexes maintained biosafety and delivered functional mRNA to target tissues without significant aggregation or immune activation, according to the reference study.

Comparison with Existing Internal Articles

These findings complement recent advances in LNP and polyplex engineering. For instance, the study on lipoamino bundle LNPs for spleen-targeted mRNA delivery demonstrated the importance of lipid chemistry for immune cell targeting. Folda et al.'s work extends this principle by showing that PEGylation and ligand attachment can be decoupled and independently optimized for both stability and specificity. Similarly, the use of dual-mode reporters such as EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) supports high-sensitivity translation efficiency assays and in vivo bioluminescence imaging, which are critical for benchmarking delivery vehicles. Collectively, these resources illustrate the rapidly evolving toolkit for non-viral mRNA delivery and the importance of combining chemical modifications with robust analytical readouts.

Limitations and Transferability

While PEGylation enhanced polyplex stability and reduced unwanted protein interactions, the study confirms that excessive PEG can mask carrier charge and impede cellular uptake—a classic "PEG dilemma." The restoration of transfection via ligand targeting is promising but may require further optimization for different cell types and ligands. Additionally, although the platform is adaptable, the in vivo data are limited to proof-of-principle studies; translation to clinical-scale manufacturing and heterogeneous patient populations will require further validation. The findings are most readily transferable to researchers developing mRNA therapeutics for tissues accessible by systemic or targeted delivery routes.

Research Support Resources

For researchers seeking to evaluate and benchmark mRNA delivery systems—including PEGylated polyplexes or ligand-functionalized nanoparticles—robust, dual-mode reporter mRNAs are invaluable. The EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) (SKU R1010) from APExBIO offers both Cy5 fluorescence for direct visualization and luciferase for sensitive quantification of translation efficiency, with a Cap1 structure and 5-moUTP modification to minimize innate immune activation. This reagent can streamline in vitro and in vivo delivery optimization, mRNA tracking, and translation efficiency assays as described in the reference study.